LEQEMBI (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimers Disease Approved in China
September 28, 2025 19:30 ET | Source: Biogen Inc. TOKYO and CAMBRIDGE,…
Advanced CAR-T Cell Therapy in a Young Engineer Battling High-Risk Pre-B Acute Lymphoblastic Leukemia
KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for…
WORK Medical Technology Group LTD Partners with Hong Kong Web3.0 Standardization Association to Collaborate on Blockchain and RWA Innovations
Hangzhou, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group…
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
Fermenta Board Approves Sale of Environmental Solutions Business to Wholly Owned Subsidiary
Strategic transfer to enhance operational focus and create dedicated environmental solutions platformTo…
Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
People taking Novo Nordisks Wegovy experienced reduced food noise and boosted mental well-being
Results from a real-world survey suggest that semaglutide for weight management (Wegovy®)…
Sirtex Receives Expanded CE Mark Approval for SIR-Spheres Y-90 Resin Microspheres
Broadened indication increases access to liver cancer treatment across Europe and CE-marked…
NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program
The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to…